<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03502408</url>
  </required_header>
  <id_info>
    <org_study_id>yan2017-150</org_study_id>
    <nct_id>NCT03502408</nct_id>
  </id_info>
  <brief_title>Perfusion Imaging Evaluation for Ischemic Stroke on 6-24 Hours Undergoing Endovascular Thrombectomy</brief_title>
  <acronym>PESET</acronym>
  <official_title>Perfusion Imaging Evaluation for Ischemic Stroke on 6-24 Hours Undergoing Endovascular Thrombectomy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Second Affiliated Hospital, School of Medicine, Zhejiang University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Second Affiliated Hospital, School of Medicine, Zhejiang University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to evaluate the hypothesis that thrombectomy devices plus medical management&#xD;
      leads to superior clinical outcomes in acute ischemic stroke patients at 90 days as compared&#xD;
      to medical management alone in appropriately selected subjects with the Target Mismatch&#xD;
      Profile and an MCA (M1 and M2 segment) or ICA occlusion or BA who have endovascular&#xD;
      thrombectomy initiated between 6-24 hours after last seen well.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study design is a prospective, single-center study of acute ischemic stroke patients with&#xD;
      large artery occlusion in 6-24 hours of stroke onset. According to patients or their family&#xD;
      members' willing, patients who meet the inclusion criteria will be assigned to endovascular&#xD;
      thrombectomy group with approved devices (only the devices listed in this protocol are&#xD;
      approved for us) plus standard medical therapy or control group (standard medical therapy&#xD;
      alone) after undergoing either CT Perfusion or MR Perfusion studies. Patients who have&#xD;
      evidence of an ICA or MCA M1 or M2 or BA occlusion and a Target Mismatch Profile will be&#xD;
      enrolled.&#xD;
&#xD;
      The intent of this study is to support thrombectomy beyond the currently labeled 8 hour&#xD;
      indicated time limit in wake up, unclear onset, and late presenting ischemic stroke subjects,&#xD;
      who currently have no other option besides medical management of their symptoms, with careful&#xD;
      selection.&#xD;
&#xD;
      The study will enroll up to 55 patients. The primary endpoint, the modified Rankin Score,&#xD;
      will be assessed at 3 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 1, 2018</start_date>
  <completion_date type="Anticipated">August 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">August 1, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Good Functional Independence</measure>
    <time_frame>90 days</time_frame>
    <description>This outcome will look at the proportion of patients with mRS 0-2 at day 90.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Death</measure>
    <time_frame>90 days</time_frame>
    <description>Death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Symptomatic Intracranial Hemorrhage</measure>
    <time_frame>24 hours</time_frame>
    <description>Defined as NIHSS worsening of 4 or more points associated with ICH within 24 hours of randomization</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">55</enrollment>
  <condition>Stroke, Acute Cerebral Infarction</condition>
  <arm_group>
    <arm_group_label>Endovascular Thrombectomy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Procedure: Endovascular Thrombectomy Device: Trepo trevor Retriever Device: Solitaire™ FR Revascularization Device</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Endovascular Thrombectomy</intervention_name>
    <description>Procedure: Endovascular Thrombectomy Device: Trepo trevor Retriever Device: Solitaire™ FR Revascularization Device</description>
    <arm_group_label>Endovascular Thrombectomy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Endovascular Thrombectomy</intervention_name>
    <description>Procedure:Endovascular Thrombectomy Device: Solitaire™ FR Revascularization Device</description>
    <arm_group_label>Endovascular Thrombectomy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Clinical Inclusion Criteria:&#xD;
&#xD;
          1. Clinical signs and symptoms consistent with the diagnosis of an acute ischemic stroke&#xD;
&#xD;
          2. Age ≥18 years&#xD;
&#xD;
          3. NIHSS ≥ 6&#xD;
&#xD;
          4. Endovascular thrombectomy can be initiated (femoral puncture) between 6 and 24 hours&#xD;
             after time last know well&#xD;
&#xD;
          5. No significant pre-stroke disability (pre-stroke mRS must be ≤ 3 )&#xD;
&#xD;
          6. Patient/Legally Authorized Representative has signed the Informed Consent form&#xD;
&#xD;
        Imaging Inclusion Criteria:&#xD;
&#xD;
          1. ICA or MCA-M1 or MCA-M2 or BA occlusion (carotid occlusions can be cervical or&#xD;
             intracranial with or without tandem MCA lesions) as evidenced by MRA or 4D-CTA&#xD;
&#xD;
          2. Target Mismatch Profile on CT perfusion or MR perfusion: ischemic core volume is ≤ 70&#xD;
             ml, mismatch ratio is &gt;/= 1.2 )&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Clinical Exclusion Criteria:&#xD;
&#xD;
          1. Other serious, advanced, or terminal illness (investigator judgment) or life&#xD;
             expectancy is less than 90 days&#xD;
&#xD;
          2. Subject with a co-morbid disease or condition that would confound the neurological and&#xD;
             functional evaluations or compromise survival or ability to complete follow-up&#xD;
             assessments&#xD;
&#xD;
          3. Unable to undergo a contrast brain perfusion scan with either MRI or CT&#xD;
&#xD;
          4. Pregnant&#xD;
&#xD;
          5. Known serious sensitivity to radiographic contrast agents&#xD;
&#xD;
          6. Treated with rtPA &gt;6 hours after time last known well&#xD;
&#xD;
          7. Known hereditary or acquired hemorrhagic diathesis, coagulation factor deficiency;&#xD;
             recent oral anticoagulant therapy with INR &gt; 3 (recent use of one of the new oral&#xD;
             anticoagulants is not an exclusion if estimated GFR &gt; 30 ml/min).&#xD;
&#xD;
          8. Seizures at stroke onset if it precludes obtaining an accurate baseline NIHSS&#xD;
&#xD;
          9. Current participation in another investigational drug or device treatment study&#xD;
&#xD;
         10. Known hereditary or acquired hemorrhagic diathesis, coagulation factor deficiency&#xD;
&#xD;
         11. Any other condition that, in the opinion of the investigator, precludes an&#xD;
             endovascular procedure or poses a significant hazard to the subject if an endovascular&#xD;
             procedure was performed.&#xD;
&#xD;
        Neuroimaging Exclusion Criteria:&#xD;
&#xD;
          1. ASPECTS score &lt;6 on non-contrast CT (if patient is enrolled based on CT perfusion&#xD;
             criteria)&#xD;
&#xD;
          2. Evidence of intracranial tumor (except small meningioma), acute intracranial&#xD;
             hemorrhage, neoplasm, subarachnoid hemorrhage, or arteriovenous malformation&#xD;
&#xD;
          3. Significant mass effect with midline shift&#xD;
&#xD;
          4. Evidence of internal carotid artery dissection&#xD;
&#xD;
          5. Intracranial stent implanted in the same vascular territory, known history of arterial&#xD;
             tortuosity, and/or other arterial disease that precludes the safe deployment/removal&#xD;
             of the thrombectomy device&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>MIN LOU, Ph.D.</last_name>
    <role>Study Director</role>
    <affiliation>Second Affiliated Hospital, School of Medicine, Zhejiang University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>MIN LOU, Ph.D.</last_name>
    <phone>8657187784811</phone>
    <email>loumingxc@vip.sina.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Second Affiliated Hospital, School of Medicine, Zhejiang University</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310009</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>MIN LOU, Ph.D.</last_name>
      <phone>8657187784811</phone>
      <email>loumingxc@vip.sina.com</email>
    </contact>
    <investigator>
      <last_name>MIN LOU, Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>March 29, 2018</study_first_submitted>
  <study_first_submitted_qc>April 10, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">April 18, 2018</study_first_posted>
  <last_update_submitted>March 19, 2020</last_update_submitted>
  <last_update_submitted_qc>March 19, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 20, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
    <mesh_term>Ischemic Stroke</mesh_term>
    <mesh_term>Cerebral Infarction</mesh_term>
    <mesh_term>Infarction</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

